Jaguar Health (JAGX) Emerging Growth Conference77 summary

Company overview and product pipeline

• Focuses on plant-derived prescription medicines for gastrointestinal distress in humans and animals, with crofelemer as the lead compound.

• Crofelemer is FDA-approved as Mytesi for HIV-related diarrhea and as Canalevia-CA1 for chemotherapy-induced diarrhea in dogs.

• Holds about 155 patents, providing long-term exclusivity and protection from generic competition.

• Eight follow-on indications identified, with prioritization on cancer therapy-related diarrhea and rare diseases.

Financial and commercial highlights

• Q3 revenue grew 14% over Q2, with consistent quarter-on-quarter growth expected to continue.

• Recently launched Gelclair for oral mucositis in cancer patients, with financial impact expected in Q4 and beyond.

• Mytesi net revenue for 2023 was about $9.6 million, with projections of $10–$12 million at current run rates.

• Gelclair could reach similar revenue with just 4% market share in its initial target segment.

Clinical and regulatory developments

• Completed phase III OnTarget trial for cancer therapy-related diarrhea; did not meet primary endpoint in all patients but achieved statistical significance in breast cancer subgroup.

• Two poster presentations on breast cancer subgroup results scheduled at the San Antonio Breast Cancer Symposium.

• Plans to use these results for an FDA briefing and possible supplemental NDA filing in 2024.

• Six clinical/regulatory catalysts expected in December, January, and February, including two phase II trials and three investigator-initiated studies in rare diseases.